Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 1
2012 1
2015 1
2016 1
2019 1
2021 4
2022 6
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J. Rosiñol L, et al. Among authors: arguinano jm. Blood. 2019 Oct 17;134(16):1337-1345. doi: 10.1182/blood.2019000241. Blood. 2019. PMID: 31484647 Free PMC article. Clinical Trial.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R, Mateos MV, Richardson PG, Sonneveld P; OCEAN (OP-103) Investigators. Schjesvold FH, et al. Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12. Lancet Haematol. 2022. PMID: 35032434 Clinical Trial.
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Medina-Herrera A, et al. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. Blood Cancer J. 2024. PMID: 38684670 Free PMC article. Clinical Trial.
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.
Encinas C, Hernandez-Rivas JÁ, Oriol A, Rosiñol L, Blanchard MJ, Bellón JM, García-Sanz R, de la Rubia J, de la Guía AL, Jímenez-Ubieto A, Jarque I, Iñigo B, Dourdil V, de Arriba F, Pérez-Ávila CC, Gonzalez Y, Hernández MT, Bargay J, Granell M, Rodríguez-Otero P, Silvent M, Cabrera C, Rios R, Alegre A, Gironella M, Gonzalez MS, Sureda A, Sampol A, Ocio EM, Krsnik I, García A, García-Mateo A, Soler JA, Martín J, Arguiñano JM, Mateos MV, Bladé J, San-Miguel JF, Lahuerta JJ, Martínez-López J; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Encinas C, et al. Among authors: arguinano jm. Blood Cancer J. 2022 Apr 19;12(4):68. doi: 10.1038/s41408-022-00652-2. Blood Cancer J. 2022. PMID: 35440057 Free PMC article.
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies.
Tamariz-Amador LE, Battaglia AM, Maia C, Zherniakova A, Guerrero C, Zabaleta A, Burgos L, Botta C, Fortuño MA, Grande C, Manubens A, Arguiñano JM, Gomez C, Perez-Persona E, Olazabal I, Oiartzabal I, Panizo C, Prosper F, San-Miguel JF, Rodriguez-Otero P, Martín-Sánchez E, Paiva B; The Asociación Vasco-Navarra de Hematología y Hemoterapia (ASOVASNA) Cooperative Group. Tamariz-Amador LE, et al. Among authors: arguinano jm. Blood Cancer J. 2021 Dec 14;11(12):202. doi: 10.1038/s41408-021-00594-1. Blood Cancer J. 2021. PMID: 34907159 Free PMC article.
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Tamariz-Amador LE, Rodríguez-Otero P, Jiménez-Ubieto A, Rosiñol L, Oriol A, Ríos R, Sureda A, Blanchard MJ, Hernández MT, Cabañas Perianes V, Jarque I, Bargay J, Gironella M, De Arriba F, Palomera L, Gonzalez-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, Casado LF, González-Rodriguez AP, López-Anglada L, Puig N, Cedena MT, Paiva B, Mateos MV, San-Miguel J, Lahuerta JJ, Bladé J, Trocóniz IF. Tamariz-Amador LE, et al. Among authors: arguinano jm. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):e844-e852. doi: 10.1016/j.clml.2022.04.024. Epub 2022 May 5. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35688793 Free article.
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.
Mateos MV, Hernández MT, Salvador C, Rubia J, de Arriba F, López-Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Arguiñano JM, Bladé J, Lahuerta JJ, San-Miguel J. Mateos MV, et al. Among authors: arguinano jm. Eur J Cancer. 2022 Oct;174:243-250. doi: 10.1016/j.ejca.2022.07.030. Epub 2022 Sep 5. Eur J Cancer. 2022. PMID: 36067617 Clinical Trial.
Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez E, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández A, Naves A, Rosiñol L. Ocio EM, et al. Among authors: arguinano jm. Clin Lymphoma Myeloma Leuk. 2022 Apr;22(4):e241-e249. doi: 10.1016/j.clml.2021.10.001. Epub 2021 Oct 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34774462 Free article.
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Rodriguez-Otero P, Sirvent M, González-Rodríguez AP, Lavilla E, de Coca AG, Arguiñano JM, Martí JM, Cabañas V, Motlló C, de Cabo E, Encinas C, Murillo I, Hernández-Rivas JÁ, Pérez-Persona E, Casado F, Sampol A, García R, Blanchard MJ, Anguita M, Lafuente AP, Iñigo B, López A, Ribas P, Arnao M, Maldonado R, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF. Rodriguez-Otero P, et al. Among authors: arguinano jm. Clin Lymphoma Myeloma Leuk. 2021 Jun;21(6):413-420. doi: 10.1016/j.clml.2021.02.004. Epub 2021 Feb 16. Clin Lymphoma Myeloma Leuk. 2021. PMID: 33741302
Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM).
Villalba A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, Arnao M, Arguiñano JM, Jimenez M, Canet M, Teruel AI, Sola M, Díaz FJ, Encinas C, Garcia A, Rosiñol L, Suárez A, Gonzalez MS, Izquierdo I, Hernández MT, Infante MS, Sánchez MJ, Sampol A, de la Rubia J. Villalba A, et al. Among authors: arguinano jm. Leuk Lymphoma. 2022 Dec;63(14):3438-3447. doi: 10.1080/10428194.2022.2123229. Epub 2022 Sep 20. Leuk Lymphoma. 2022. PMID: 36124538
17 results